[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PhilipHemme "Paying high prices fuels drug innovation Amgen $AMGN still made $3.3B in 2024 from Enbrel a 27-year-old drug off-patent since 2016 with XX% of sales in the US. Not sure if price caps like Colorados are the fix but it might help Thoughts @PeterKolchinsky @LifeSciVC"
X Link @PhilipHemme 2025-10-04T04:30Z 6263 followers, 1651 engagements

"NEWS: BioNTech ( $BNTX) just unveiled positive interim Ph2 results for its PD-L1VEGF bispecific. A potential blockbuster and strong challenger to Summit ( $SMMT) & 3SBio 👀"
X Link @PhilipHemme 2025-09-09T04:02Z 6262 followers, 1805 engagements

"RECORDING: in 1998 pioneering biotech Pharming $PHAR $PHARM was founded. In March Fabrice took over to lead its next chapter"
X Link @PhilipHemme 2025-10-07T15:19Z 6262 followers, XXX engagements

"Friday night recording with Laurent from Nanobiotix now a billion-dollar biotech $NBTX $NANO"
X Link @PhilipHemme 2025-10-17T16:22Z 6262 followers, XXX engagements

"Context: The data follow the massive June 2025 deal between BioNTech and BMS ($1.5B upfront). Competition is fierce with rival PD-(L)1VEGF bispecifics from Akeso/Summit and Pfizer/3SBio advancing fast as well. The update also comes shortly after a Ph3 ADC win reinforcing BioNTechs growing oncology footprint. Despite the clinical progress the stock spiked XX% on the news before falling back to baseline"
X Link @PhilipHemme 2025-09-09T04:02Z 6261 followers, XXX engagements

"Big private takeover for $BAVA"
X Link @PhilipHemme 2025-07-29T01:11Z 6262 followers, XXX engagements

"EPISODE: Raising a $60M Series C in 2025 is tough. Daniela just did it to bring a breakthrough tissue therapeutic to the market The funding round is a testament to the fact that when there is a good product with good science and a clear unmet need.it is possible to find the right investors said CEO and co-founder Daniela Marino. She explains how @Cutiss_AG is building a decentralised production model for its tissue therapeutic that could replace skin grafts for severe burns. You can be as close as you can to the largest hospitals and try to serve the patients in a quicker and cheaper way. She"
X Link @PhilipHemme 2025-10-14T08:00Z 6261 followers, XXX engagements

"EPISODE (40 🥳): Azafaros raised a massive $147M Series B round in May. The surprising part It didnt even need US investors This testifies to the fact that Europe is finally playing a big role in this type of environmentTo me thats great news says CEO Stefano Portolano. Azafaros is using the cash to develop the small molecule nizubaglustat for the treatment of rare conditions known as lysosomal storage disorders with two phase X trials kicking off this year. I think theres a revival of small molecules Stefano says adding that unlike many biologics small molecules have the potential to serve"
X Link @PhilipHemme 2025-10-02T08:00Z 6261 followers, XXX engagements

"Which biotech didn't you know 🤔 Top 10: $ARGX $BNTX $GMAB $ASND $SOBI $ABVX $MRUS $ZEAL $CAMRF $MLTX. $XBI"
X Link @PhilipHemme 2025-09-16T08:43Z 6262 followers, 43.1K engagements

"Who are the biggest biotechs in Europe 🤩 Want access to the data 👉 Want full access to the data in a digital web appwith list view market caps pipelines and therapeutic areas Comment Map and Ill send it to you rapidly 💬 Top 10: $ARGX $BNTX $GMAB $ASND $SOBI $ABVX $MRUS $ZEAL $CAMRF $MLTX"
X Link @PhilipHemme 2025-09-15T08:02Z 6262 followers, 1932 engagements